Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors

Cancer Research

Volumn 65, Issue 5, 2005, Pages 1719-1728

  Kitlinska, Joanna ^a,b   Abe, Ken ^a   Kuo, Lydia ^a   Pons, Jennifer ^a   Yu, Muchieh ^a   Li, Lijun ^a   Tilan, Jason ^a   Everhart, Lindsay ^a   Lee, Edward W ^a   Zukowska, Zofia ^a   Toretsky, Jeffrey A ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; EWING SARCOMA; HUMAN; HUMAN CELL; MOUSE; NEURAL CREST; NEUROBLASTOMA; NEUROENDOCRINE TUMOR; NONHUMAN; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; NEUROPEPTIDE Y; PHEOCHROMOCYTOMA; RATS; RECEPTORS, NEUROPEPTIDE Y; TRANSPLANTATION, HETEROLOGOUS;

EID: 20144389703     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2192     Document Type: Article

References (47)

1. Biedler JL, Roffler-Tarlov S, Schachner M, Freedman LS. Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. Cancer Res 1978;38:3751-7.
2. O'Hare MM, Schwartz TW. Expression and precursor processing of neuropeptide Y in human and murine neuroblastoma and pheochromocytoma cell lines. Cancer Res 1989;49:7015-9.
3. van Valen F, Winkelmann W, Jurgens H. Expression of functional Y1 receptors for neuropeptide Y in human Ewing's sarcoma cell lines. J Cancer Res Clin Oncol 1992;118:529-36.
4. Fruhwald MC, O'Dorisio MS, Cottingham SL, Qualman SJ, O'Dorisio TM. Neuropeptides in developmental tumors of the central and peripheral nervous system. Ann N Y Acad Sci 1998;865:420-6.
5. Kuvshinoff BW, Nussbaum MS, Richards AI, Bloustein P, McFadden DW. Neuropeptide Y secretion from a malignant extraadrenal retroperitoneal paraganglioma. Cancer 1992;70:2350-3.
6. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16.
7. Dotsch J, Christiansen H, Hanze J, Lampert F, Rascher W. Plasma neuropeptide Y of children with neuroblastoma in relation to stage, age and prognosis, and tissue neuropeptide Y. Regul Pept 1998;75-76:185-90.
8. Nakagawara A. Molecular basis of spontaneous regression of neuroblastoma: role of neurotrophic signals and genetic abnormalities. Hum Cell 1998;11:115-24.
9. Nakagawara A. The NGF story and neuroblastoma. Med Pediatr Oncol 1998;31:113-5.
10. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996;14:405-14.
11. Chlenski A, Liu S, Cohn SL. The regulation of angiogenesis in neuroblastoma. Cancer Lett 2003;197:47-52.
12. Erdreich-Epstein A, Shimada H, Groshen S, et al. Integrins α(v)β3 and α(v)β5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000;60:712-21.
13. Beltinger C, Debatin KM. Murine models for experimental therapy of pediatric solid tumors with poor prognosis. Int J Cancer 2001;92:313-8.
14. de Alava E, Gerald WL. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J Clin Oncol 2000;18:204-13.
15. Gorlick R, Anderson P, Andrulis I, et al. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003;9:5442-53.
16. Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 1989;7:1720-5.
17. Grouzmann E, Comoy E, Bohuon C. Plasma neuropeptide Y concentrations in patients with neuroendocrine tumors. J Clin Endocrinol Metab 1989;68:808-13.
18. Pruszczyk P, Wocial B, Ignatowska-Switalska H, et al. Does plasma neuropeptide-Y immunoreactivity in patients with pheochromocytoma depend on hormonal activity of the tumor? Clin Chim Acta 1995;243:205-12.
19. Colmers WF, Wahlestedt C. The biology of neuropeptide and related peptides. Totowa (NJ): Humana Press; 1993.
20. Hansel DE, Eipper BA, Ronnett GV. Neuropeptide Y functions as a neuroproliferative factor. Nature 2001;410:940-4.
21. Pons J, Kitlinska J, Ji H, Lee EW, Zukowska Z. Mitogenic actions of neuropeptide Y in vascular smooth muscle cells: synergetic interactions with the β-adrenergic system. Can J Physiol Pharmacol 2003;81:177-85.
22. Lee EW, Michalkiewicz M, Kitlinska J, et al. Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles. J Clin Invest 2003;111:1853-62.
23. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Rose W, et al. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ Res 1998;83:187-95.
24. Kitlinska J, Lee EW, Movafagh S, Pons J, Zukowska Z. Neuropeptide Y-induced angiogenesis in aging. Peptides 2002;23:71-7.
25. Cabrele C, Beck-Sickinger AG. Molecular characterization of the ligand-receptor interaction of the neuropeptide Y family. J Pept Sci 2000;6:97-122.
26. Mentlein R. Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides. Regul Pept 1999;85:9-24.
27. Ekstrand AJ, Cao R, Bjorndahl M, et al. Deletion of neuropeptide Y (NPY) 2 receptor in mice results in blockage of NPY-induced angiogenesis and delayed wound healing. Proc Natl Acad Sci U S A 2003;100:6033-8.
28. Lee EW, Grant DS, Movafagh S, Zukowska Z. Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice. Peptides 2003;24:99-106.
29. Uren A, Merchant MS, Sun CJ, et al. β-Platelet-derived growth factor receptor mediates motility and growth of Ewing's sarcoma cells. Oncogene 2003;22:2334-42.
30. Wassberg E. Angiostatic treatment of neuroblastoma. Ups J Med Sci 1999;104:1-24.
31. Zukowska-Grojec Z, Karwatowska-Prokopczuk E, Fisher TA, Ji H. Mechanisms of vascular growth-promoting effects of neuropeptide Y: role of its inducible receptors. Regul Pept 1998;75-76:231-8.
32. Rascher W, Kremens B, Wagner S, Feth F, Hunneman DH, Lang RE. Serial measurements of neuropeptide Y in plasma for monitoring neuroblastoma in children. J Pediatr 1993;122:914-6.
33. Cohen PS, Cooper MJ, Helman LJ, Thiele CJ, Seeger RC, Israel MA. Neuropeptide Y expression in the developing adrenal gland and in childhood neuroblastoma tumors. Cancer Res 1990;50:6055-61.
34. Kogner P, Bjork O, Theodorsson E. Plasma neuropeptide Y in healthy children: influence of age, anaesthesia and the establishment of an age-adjusted reference interval. Acta Paediatr 1994;83:423-7.
35. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001;169:107-14.
36. Brodeur GM, Nakagawara A, Yamashiro DJ, et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J Neurooncol 1997;31:49-55.
37. Donovan MJ, Lin MI, Wiegn P, et al. Brain derived neurotrophic factor is an endothelial cell survival factor required for intramyocardial vessel stabilization. Development 2000;127:4531-40.
38. Barnea A, Roberts J. Induction of functional and morphological expression of neuropeptide Y (NPY) in cortical cultures by brain-derived neurotrophic factor (BDNF): evidence for a requirement for extracellular-regulated kinase (ERK)-dependent and ERK-independent mechanisms. Brain Res 2001;919:57-69.
39. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
40. Scotlandi K, Benini S, Sarti M, et al. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res 1996;56:4570-4.
41. Langer M, Kratz F, Rothen-Rutishauser B, Wunderli-Allenspach H, Beck-Sickinger AG. Novel peptide conjugates for tumor-specific chemotherapy. J Med Chem 2001;44:1341-8.
42. Reubi JC, Gugger M, Waser B, Schaer JC. Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. Cancer Res 2001;61:4636-41.
43. Shorter NA, Pence JC. Retinoic acid-induced regulation of neuropeptide Y receptor expression and function in the neuroepithelioma line SK·N·MC. J Pediatr Surg 1997;32:721-3.
44. Grise KR, Rongione AJ, Laird EC, McFadden DW. Peptide YY inhibits growth of human breast cancer in vitro and in vivo. J Surg Res 1999;82:151-5.
45. Yu A, Somasundar P, Balsubramaniam A, Rose AT, Vona-Davis L, McFadden DW. Vitamin E and the Y4 agonist BA-129 decrease prostate cancer growth and production of vascular endothelial growth factor. J Surg Res 2002;105:65-8.
46. Liu CD, Slice LW, Balasubramaniam A, et al. Y2 receptors decrease human pancreatic cancer growth and intracellular cyclic adenosine monophosphate levels. Surgery 1995;118:229-35; discussion 35-6.
47. Middeke M, Hoffmann S, Hassan I, Wunderlich A, Hofbauer LC, Zielke A. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diabetes 2002;110:386-92.